What Is IV Vitamin C

High-dose IV vitamin C is the intravenous administration of ascorbic acid at doses typically ranging from 15 to 100 grams per session, far exceeding what the gastrointestinal tract can absorb. By entering the bloodstream directly, it reaches plasma concentrations that shift its biological role from antioxidant nutrient to pharmacologic agent. It is used in integrative medicine for immune support, as adjunctive oncology care, and in certain inflammatory and infectious conditions.

Vitamin C is essential for collagen synthesis, immune cell function, and protection against oxidative damage, but at standard dietary or supplement doses it operates within a narrow physiological range. The intestine actively limits absorption, so even megadose oral supplements cannot push blood levels past a ceiling. IV delivery removes that ceiling, creating a fundamentally different pharmacologic environment in which ascorbate generates hydrogen peroxide selectively in certain tissues. This distinction matters because many of the proposed clinical applications, including selective cytotoxicity toward cancer cells, depend on achieving concentrations that are physically impossible through oral intake.

From a longevity perspective, the interest in high-dose IV vitamin C centers on three areas: reducing chronic inflammation, supporting immune resilience as it declines with age, and potentially modifying the tumor microenvironment. Chronic low-grade inflammation, sometimes called inflammaging, accelerates tissue damage and is implicated in cardiovascular disease, neurodegeneration, and metabolic dysfunction. Whether pharmacologic-dose vitamin C meaningfully alters these trajectories in otherwise healthy adults remains an open question, but the mechanistic rationale has attracted substantial clinical investigation.

At nutritional concentrations (micromolar range), ascorbic acid donates electrons to neutralize free radicals, functioning as a classical antioxidant. It also serves as a cofactor for enzymes involved in collagen hydroxylation, carnitine biosynthesis, and the hydroxylation of hypoxia-inducible factor (HIF). These are its well-established physiological roles, supported by decades of biochemistry.

When plasma concentrations reach the millimolar range through IV delivery, ascorbate participates in a different reaction. In the extracellular fluid surrounding cells, it donates an electron to dissolved oxygen and to trace metal ions (particularly iron), generating hydrogen peroxide (H₂O₂). Normal cells neutralize this peroxide efficiently using catalase and glutathione peroxidase. Cells with lower antioxidant enzyme capacity, including many cancer cell types, are less able to detoxify the peroxide and sustain oxidative damage. This selective pro-oxidant mechanism is the basis for IV vitamin C's investigation in oncology.

Beyond the pro-oxidant pathway, pharmacologic ascorbate influences immune function by enhancing neutrophil chemotaxis, lymphocyte proliferation, and natural killer cell activity. It also modulates the epigenetic landscape through its role as a cofactor for TET (ten-eleven translocation) enzymes, which demethylate DNA. TET-dependent demethylation is involved in immune cell differentiation and may influence gene expression patterns associated with cellular aging. Additionally, high-dose ascorbate downregulates several pro-inflammatory signaling cascades, including NF-kB, which orchestrates the expression of cytokines involved in chronic inflammation.

Before the first session, expect a blood draw for G6PD status, comprehensive metabolic panel, and possibly baseline inflammatory markers. The infusion itself involves placement of a standard peripheral IV catheter, typically in the forearm. The ascorbic acid is diluted in sterile water or normal saline and infused slowly over 90 minutes to 3 hours depending on the dose.

During the infusion, most people feel little beyond mild coolness at the IV site. Some experience a slight metallic taste, mild nausea, or lightheadedness, particularly at higher doses. Drinking water and having a light meal beforehand helps reduce these effects. After the session, it is common to feel a sense of increased energy or mental clarity, though individual responses vary. Occasional fatigue on the day of infusion has also been reported.

The clinical setting is typically a quiet infusion room with reclining chairs. Sessions are long enough that many patients bring reading material or use the time to rest. Vital signs may be checked during the infusion, especially during the initial dose-escalation phase.

Protocols vary depending on the clinical goal. For general immune support or wellness applications, one session per week for 4 to 8 weeks is a common starting framework, followed by periodic maintenance infusions (monthly or quarterly). In adjunctive oncology settings, twice-weekly infusions are more typical and may continue for the duration of chemotherapy cycles or longer.

Doses usually start at 15 to 25 grams for the first session and escalate over subsequent visits to the target range, which can be anywhere from 50 to 100 grams depending on the practitioner's protocol and the patient's tolerance. The pace of escalation depends on how the patient responds and what the labs show. Reassessment after 8 to 12 weeks typically guides whether to continue, adjust dosing, or transition to a maintenance schedule.

Individual sessions of high-dose IV vitamin C generally cost between $150 and $400 in the United States, depending on the dose, the clinic setting, and geographic location. Higher doses (75 grams and above) tend to be at the upper end due to the increased amount of pharmaceutical-grade ascorbic acid and longer infusion times. Some clinics offer package pricing for multi-session courses, which can reduce the per-session cost. Insurance rarely covers this therapy except in specific clinical trial contexts. Total out-of-pocket cost for a standard 8 to 12 week course at once-weekly frequency falls roughly in the $1,200 to $4,800 range before any lab work or initial consultation fees.

The clinical evidence for high-dose IV vitamin C spans several domains but remains uneven in quality. In oncology, phase I and phase II trials have examined its use alongside standard chemotherapy in cancers of the pancreas, ovary, lung, and brain. These studies generally report improved quality of life, reduced chemotherapy side effects, and acceptable safety, but they are not large enough or designed to establish whether IV vitamin C extends survival. A few randomized controlled trials have been completed, but most have small sample sizes. The National Cancer Institute notes the biological plausibility of the pro-oxidant mechanism while emphasizing that definitive efficacy data is lacking.

Outside oncology, IV vitamin C has been studied in sepsis and critical illness, where early enthusiasm from observational data was tempered by subsequent randomized trials showing limited or no benefit on mortality. Research in viral infections, including influenza and COVID-19, has produced mixed results, with some trials reporting shortened symptom duration and others finding no significant difference. For general immune support and anti-aging applications in healthy individuals, controlled trial data is sparse. Much of the mechanistic understanding comes from in vitro and animal research, which does not always translate to human outcomes. The field would benefit from larger, well-designed randomized trials with clearly defined endpoints.

The most serious risk is hemolytic anemia in individuals with undiagnosed G6PD deficiency, which is why screening before the first infusion is standard. Oxalate nephropathy, where high levels of oxalate (a metabolite of ascorbate) damage the kidneys, is a concern for those with pre-existing kidney disease or a history of oxalate stones. Rapid infusion can cause vein irritation, nausea, lightheadedness, or drops in blood pressure. High-dose vitamin C can interfere with glucometer readings, producing falsely elevated blood sugar values, which is clinically important for diabetic patients. Those with iron overload disorders should avoid high-dose ascorbate because it enhances iron absorption. Coordination with oncologists is essential for cancer patients, as pharmacologic ascorbate may theoretically interact with certain chemotherapy agents or radiation protocols, though evidence on this point is still evolving.